In today’s R&D environment, predictive patient recruitment and improving phase III success rates are key ways to drive more robust R&D productivity and get new and improved products in the hands of patients who count on them. After all, you’re investing over $800M per product these days.
Our 25 years of experience in Phase I-IV study design and management, leveraging our eClinical technologies, gives PAREXEL the ability to provide flexible, tailored expertise to drive product value from discovery to market. Our global investigator and patient recruitment expertise means rapid enrollment and start-up. Our industry leading early phase and unique Proof of Concept capabilities means faster go/no-go decisions and better Phase III outcomes.
- Biomarker Analysis and Development
- Clinical Development and Consulting Phases I-IV
- Predictive Patient Recruitment
- eClinical technologies: EDC, CTMS, IVRS/IWRS, Medical Imaging
- Comprehensive Labeling Services
- Clinical Trial Regulatory Services for Global Submissions
- GxP Strategic Compliance and Quality
- Safety/ Pharmacovigilance Program Design and Management
- Strategic Reimbursement Patient Access Programs
Featured Experts: Imogene Grimes, Ph.D , Dr. George Q. Mills,
Dr. Udo Kiesling, Dr. Han Van Bronswijk, Dr. Uwe Maenni
Contact us today to discuss your key to product development success.
